Last reviewed · How we verify

Lumakras — Competitive Intelligence Brief

Lumakras (SOTORASIB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed GTPase KRas Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lumakras (SOTORASIB) — Amgen. Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lumakras TARGET SOTORASIB Amgen marketed GTPase KRas 2021-01-01
Krazati ADAGRASIB Bristol-Myers Squibb marketed GTPase KRas 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumakras — Competitive Intelligence Brief. https://druglandscape.com/ci/sotorasib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: